VK Gadi, MD, PhD

Articles by VK Gadi, MD, PhD

Potential Role of Surgery in HER2+ Metastatic Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 23rd 2022

Shared insight on the potential role for surgery in the setting of HER2+ metastatic breast cancer in the context of pharmacologic therapy.

SABCS 2021: Small Molecule Clinical Trials in R/R HER2+ mBC

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 23rd 2022

Rounding out their conversation on SABCS 2021, experts discuss small molecule–based treatment strategies for relapsed/refractory HER2+ metastatic breast cancer.

SABCS 2021: Combination Strategies Under Investigation for R/R HER2+ mBC

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 16th 2022

Considering data from the SABCS 2021 annual meeting, experts discuss novel combination strategies for relapsed/refractory HER2+ metastatic breast cancer.

HER2+ Breast Cancer: Updates on HER2CLIMB and CNS Disease Management

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 16th 2022

A brief review of updated data from HER2CLIMB and discussion on which agents may be best for treating patients with CNS disease.

Novel Treatment Approaches to R/R HER2+ Metastatic Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 9th 2022

Experts discuss the role of novel therapies in relapsed/refractory HER2+ metastatic breast cancer accounting for results from recent clinical trial.

HER2+ mBC: Impact of T-DM1 and T-DXd Beyond the Frontline Setting

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 9th 2022

Shared insight on the roles of trastuzumab emtansine and trastuzumab deruxtecan in relapsed/refractory HER2+ metastatic breast cancer.

Monitoring Patients With HER2+ Metastatic Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 2nd 2022

A brief review of patient monitoring and screening practices in the setting of HER2+ metastatic breast cancer.

Patient Case: Frontline Treatment Options for HER2+ mBC

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 2nd 2022

Taking into account a patient case of HER2+ metastatic breast cancer, experts review current frontline treatment options.

Patient Case: Biomarker Testing in Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

January 26th 2022

Centered on a patient presentation of breast cancer, panelists consider optimal biomarker testing strategies to inform their treatment approach.

An Overview on the Current State of Metastatic Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

January 26th 2022

Expert perspectives on the current treatment landscape of metastatic breast cancer and the unmet needs prevalent across various subsets of disease.

VK Gadi, MD, PhD

Articles by VK Gadi, MD, PhD

Potential Role of Surgery in HER2+ Metastatic Breast Cancer

SABCS 2021: Small Molecule Clinical Trials in R/R HER2+ mBC

SABCS 2021: Combination Strategies Under Investigation for R/R HER2+ mBC

HER2+ Breast Cancer: Updates on HER2CLIMB and CNS Disease Management

Novel Treatment Approaches to R/R HER2+ Metastatic Breast Cancer

HER2+ mBC: Impact of T-DM1 and T-DXd Beyond the Frontline Setting

Monitoring Patients With HER2+ Metastatic Breast Cancer

Patient Case: Frontline Treatment Options for HER2+ mBC

Patient Case: Biomarker Testing in Breast Cancer

An Overview on the Current State of Metastatic Breast Cancer

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma